Clinical Trial Update: Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD [Phase 2, Phase 3]

View source ↗

Summary

A pediatric Phase 2/3 study is evaluating Ravulizumab IV for Neuromyelitis Optica Spectrum Disorder. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 2, Phase 3 | Status: RECRUITING